Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11;5(1):24.
doi: 10.1186/s41181-020-00110-z.

Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Isaac M Jackson  1   2 , So Jeong Lee  1   3 , Alexandra R Sowa  1 , Melissa E Rodnick  1 , Laura Bruton  1 , Mara Clark  1 , Sean Preshlock  1 , Jill Rothley  1 , Virginia E Rogers  1 , Leslie E Botti  1 , Bradford D Henderson  1 , Brian G Hockley  1 , Jovany Torres  1 , David M Raffel  1 , Allen F Brooks  1 , Kirk A Frey  1 , Michael R Kilbourn  1 , Robert A Koeppe  1 , Xia Shao  1 , Peter J H Scott  4
Affiliations

Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Isaac M Jackson et al. EJNMMI Radiopharm Chem. .

Abstract

Background: In the US, EU and elsewhere, basic clinical research studies with positron emission tomography (PET) radiotracers that are generally recognized as safe and effective (GRASE) can often be conducted under institutional approval. For example, in the United States, such research is conducted under the oversight of a Radioactive Drug Research Committee (RDRC) as long as certain requirements are met. Firstly, the research must be for basic science and cannot be intended for immediate therapeutic or diagnostic purposes, or to determine the safety and effectiveness of the PET radiotracer. Secondly, the PET radiotracer must be generally recognized as safe and effective. Specifically, the mass dose to be administered must not cause any clinically detectable pharmacological effect in humans, and the radiation dose to be administered must be the smallest dose practical to perform the study and not exceed regulatory dose limits within a 1-year period. In our experience, the main barrier to using a PET radiotracer under RDRC approval is accessing the required information about mass and radioactive dosing.

Results: The University of Michigan (UM) has a long history of using PET radiotracers in clinical research studies. Herein we provide dosing information for 55 radiotracers that will enable other PET Centers to use them under the approval of their own RDRC committees.

Conclusions: The data provided herein will streamline future RDRC approval, and facilitate further basic science investigation of 55 PET radiotracers that target functionally relevant biomarkers in high impact disease states.

Keywords: Dosimetry; IND; PET imaging; Quality assurance; RDRC; Radiopharmaceuticals; Regulatory oversight.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Fig. 1
Fig. 1
Regulatory Oversight for PET Drugs in the United States
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–1620. - PubMed
    1. Albin R, Koeppe R, Bohnen N, Wernette K, Kilbourn M, Frey K. Spared caudal brainstem SERT binding in early Parkinson disease. J Cereb Blood Flow Metab. 2008;28:441–444. - PubMed
    1. Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72:1390–1396. - PMC - PubMed
    1. Alves VH, Abrunhosa AJ, Castelo-Branco M. Optimisation of synthesis, purification and reformulation of (R)-[N-Methyl-11C]PK11195 for in vivo PET imaging studies. In Proceedings of the 2013 IEEE 3rd Portuguese Meeting in Bioengineering (ENBENG), Braga, Portugal, 20–23 February 2013; pp. 1–5.
    1. Aznavour N, Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology. 2007;52:695–707. - PubMed

LinkOut - more resources